ArticleNPJ precision oncology2024
The clinical outcome, pathologic spectrum, and genomic landscape for 454 cases of salivary mucoepidermoid carcinoma.
Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Clinicopathologic characteristics and prognostic factors of mucoepidermoid carcinoma: a 20-year real-world cohort study.ESMO real world data and digital oncology · 2026Article
- Parotid mucoepidermoid carcinoma presenting as a cutaneous mass.JAAD case reports · 2026Article
- Thrombospondin-1 triggers calreticulin expression in human mucoepidermoid carcinoma MC-3 cells via the PERK/CHOP pathway.Oncology letters · 2026Article
- Does the site of origin of mucoepidermoid carcinoma impact treatment outcomes? Long-term analysis of 244 patients over a decade.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Primary high-grade mucoepidermoid carcinoma of the lacrimal gland: retrospective clinical-pathologic analysis of 20 cases.BMC ophthalmology · 2026Article
- Role of Ki-67 and Annexin V in the Biological Behavior of Salivary Gland Tumors: Insights into Proliferation and Apoptosis.Current issues in molecular biology · 2026Article
- Trends and Disparities in Mortality from Malignant Parotid Gland Tumors in the United States, 1999-2023: A Population-Based Analysis.Cancer informatics · 2026Article
- Case report of a rare postoperative cervical lymph node metastasis of palate mucoepidermoid carcinoma.Frontiers in oncology · 2026Article
- Risk-adapted neck dissection in salivary gland carcinoma: integrating occult nodal metastasis patterns with contemporary guidelines.Frontiers in oncology · 2026Review
- A scientometric study on research trends and characteristics of mucoepidermoid carcinoma of salivary glands.Journal of dental sciences · 2026Article
- Mucoepidermoid carcinoma of the middle ear: a case report.Frontiers in surgery · 2026Article
- Article
- The Molecular Biology of MEC Salivary Gland Tumors.Annals of otolaryngology and rhinology · 2025Article
- Unilocular cystic mucoepidermoid carcinoma: 6 cases reported and literature review.International journal of clinical and experimental pathology · 2025Article
- Case Report: A pediatric case of the clear-cell variant of mucoepidermoid carcinoma in the palate harboringFrontiers in pediatrics · 2025Article
- Warthin-like Mucoepidermoid Carcinoma in an Elderly Male Patient: A Case Report.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucoepidermoid carcinoma (MEC) is the most common malignant salivary tumor. A complete understanding of the high heterogeneity of MEC in histology and genetics would help in accurate diagnosis and treatment. Therefore, We evaluated the clinical features, treatment outcomes, and pathological parameters of 454 MECs and analyzed their genomic features using whole-exome sequencing and whole-transcriptome sequencing. We found that MECs predominantly occurred in females and those in their 4th-5th decades. The parotid gland was the most frequently affected site. All patients underwent complete mass resection with lobectomy; 414 patients were alive without relapse at follow-up, after an average period of 62 months (1-116 months). The disease progressed after initial treatment in 40 patients. The lungs were the most common site of distant metastasis. For classical MECs, histologic gradings of the AFIP, modified Healey, and MSK systems were significantly associated with recurrence and lymph nodal metastasis; these gradings were significantly related to lymph nodal metastasis for the subtypes. Older age, minor salivary gland involvement, clinical symptoms, high TNM stage, high-grade tumor, and improper surgical modality were the main prognostic factors. BAP1 was the most frequently mutated gene in MEC. Mutations in CDKN2A, MET, and TP53 were more frequently found in aggressive tumor phenotypes. MAML2 rearrangement was observed in 42% of patients, and EWSR1 rearrangement in 8%. Specific genetic events (in TP53 and FBXW7) with CRTC1::MAML2 fusion superimposed might be associated with unfavorable prognosis. This study provides new insights into precision therapeutic strategies for MEC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.